Disitamab Vedotin: 2.0 mg/kg administered intravenously every three weeks
Lenvatinib: ≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily
Pembrolizumab: 200 mg intravenously every three weeks
Toripalimab: 240 mg intravenously every three weeks
Camrelizumab: 200 mg intravenously every three weeks
Study summary
This trial is a single-arm exploratory phase II clinical study initiated by the investigator.
Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with lenvatinib and PD-1 inhibitor. During the treatment process, the researchers closely followed up, strictly evaluated the efficacy, assessed the efficacy and safety of the subjects after receiving the combined treatment, evaluated the subjects until progression occurred, and observed their objective response rate, progression-free survival, overall survival, disease control rate, duration of response, and safety evaluation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria:
1. Participants who voluntarily participate in this study, sign the written informed consent, and are able to comply with the protocol.
2. Age ≥ 18 years and any gender.
3. Histologically or cytologically confirmed unresectable locally advanced or metastatic biliary tract cancer (BTC), including intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC).
4. At least one measurable lesion (according to RECIST 1.1).
5. ECOG performance status score of 0-1.
6. Child-Pugh score ≤ 7 .
7. HER2 expression confirmed by: Immunohistochemistry (IHC 2+ or 3+); or Fluorescence in situ hybridization (FISH) with HER2/CEP17 ratio ≥2.0; or Next-generation sequencing (NGS) showing HER2 amplification.
8. No prior HER2-targeted therapy (including antibody-based agents, small-molecule TKIs, or antibody-drug conjugates) before randomization.
9. Expected survival \> 12 weeks.
10. Adequate hematological and major organ function.
Exclusion criteria：
1. Histological or cytological diagnosis of combined hepatocellular-cholangiocarcinoma (cHCC-CCA), mucinous adenocarcinoma, sarcoma, or neuroendocrine tumors.
2. Pregnant women (positive pregnancy test before medication) or lactating women.
3. Known allergy or intolerance to disitamab vedotin, lenvatinib, PD-1 inhibitors, or their excipients.
4. History of other active malignancies within 5 years prior to screening.
5. Presence of central nervous system metastasis and/or leptomeningeal metastasis.
6. Unhealed severe wounds, active ulcers, or untreated fractures.
7. Administration of live vaccines within 30 days prior to randomization.
8. Active autoimmune disease or history of autoimmune disease.
9. Presence of clinically significant gastrointestinal disorders.
10. Presence of clinically significant cardiovascular or cerebrovascular diseases.
Primary outcome measure(s)
ORR, objective response rate — 12 months after the last subject is enrolled
Trial sites (1)
Facility
City
Region
Status
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.